Chimerix Stock News

Chimerix press release (CMRX): Q4 GAAP EPS of -$0.45 misses by $0.28.Revenue of $0.05M (-95.5% Y/Y) misses by $18.01M.

– TEMBEXA RFP Response Submitted and Under Review with BARDA –

Chimerix (CMRX) delivered earnings and revenue surprises of -309.09% and 99.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (NASDAQ:CMRX) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is $0.13 and the consensus Revenue Estimate…

DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patien

DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer and Mike Andriole, Chief Financial and Business Officer, will participate in a fireside chat at the Cowen and Company 42nd Annual Health Care Conference on Monday, March 7, 2022 at 12:50 p.m. ET.

DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients

Vapotherm (VAPO) delivered earnings and revenue surprises of -14.52% and 2.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Chimerix Inc''s (NASDAQ: CMRX ) preclinical data from its CMX521 program will be featured at the International Conference on Antiviral Research (ICAR) in March. In vivo, studies were performed in an animal model used during the development of a different antiviral therapy that obtained FDA Emergency Use Authorization for SARS-CoV-2. Monotherapy prophylactic administration of aerosol CMX521 every eight hours starting eight … Full story available on Benzinga.com

DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patien

DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Tuesday, March 1, 2022 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2021, and to provide a business overview.

DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients

Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chimerix (CMRX) has lost ~2.9% in the post-market after announcing that the journal, Clinical Cancer Research, published details on its Phase 2 study for the orally administered…